摘要
目的：观察新型强效选择性β１受体阻断剂塞利络尔（Ｃｅｌｉｐｒｏｌｏｌ，Ｃｅｌｉ）对原发性高血压的临床疗效。方法：以进口选择性β１受体阻断剂中作用时效最长的比索络尔（Ｂｉｓｏｐｒｏｌｏｌ，Ｂｉｓｏ）为对照，采取双盲、随机、平行对照的方法进行研究。６８例轻～中度原发性高血压患者随机分入Ｃｅｌｉ组（ｎ＝３４）和Ｂｉｓｏ组（ｎ＝３４），总疗程为６周。结果：①Ｃｅｌｉ及Ｂｉｓｏ有明显的降压疗效，且疗效相似；②Ｃｅｌｉ减慢心率作用相对较轻；③二者均无明显而严重的副作用。结论：Ｃｅｌｉ在原发性高血压的治疗中是一种安全、有效的药物。
Objective: To observe the therapeutic effects of celiprolol (Celi), a selective blocker for β1 receptor, on essential hypertension. Methods: A doubleblind random comparative study was conducted between Celi and bisoprolol (Biso) in 68 patients aged 40～65 years with mild to moderate essential hypertension (diastolic BP 95～115 mmHg). The patients were randomly assigned to receive either Celi (n=34) or Biso (n=34) for 6 weeks. Changes in blood pressure, heart rate and side effects were observed. Results: 1) Both Celi and Biso led to a similar and significant reduction of diastolic and systolic blood pressure. 2) Celi exerted less effects on heart rate than Biso. 3) Both Celi and Biso had no remarkable side effects. Conclusion: Celi is a safe and effective agent in treatment of essential hypertension.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
1997年第6期530-533,共4页
Journal of Third Military Medical University
